Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase Clinical Trial

Official title:
PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS

Status Recruiting

Clinical Trial Summary

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on dasatinib.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
Myelogenous Leukemia, Chronic, Chronic Phase

Clinical Trial Details

NCT number	NCT01887561
Study type	Interventional
Source	Kanto CML Study Group
Contact
Status	Recruiting
Phase	Phase 2
Start date	November 2012

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT00038649` - Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C	Phase 2
	Recruiting	`NCT01464411` - Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan	N/A